Cat poop parasite may help cure cancer

Image
Press Trust of India Washington
Last Updated : Jul 16 2014 | 3:17 PM IST
A mutated strain of a cat poop parasite has been found to reprogramme the natural power of the immune system to kill cancer cells, scientists say.
Toxoplasma gondii (T gondii) is a single-celled parasite found in a cat's intestines, but it can live in any warm blooded animal.
T gondii affects about one-third of the world's population. Most people have no symptoms, but some experience a flu-like illness. Those with suppressed immune systems, however, can develop a serious infection if they are unable to fend off T gondii.
A healthy immune system responds vigorously to T gondii in a manner that parallels how the immune system attacks a tumour.
"We know biologically this parasite has figured out how to stimulate the exact immune responses you want to fight cancer," said David J Bzik, professor of Microbiology and Immunology, Geisel School of Medicine at Dartmouth.
In response to T gondii, the body produces natural killer cells and cytotoxic T cells. These cell types wage war against cancer cells. Cancer can shut down the body's defensive mechanisms, but introducing T gondii into a tumour environment can jump start the immune system.
"The biology of this organism is inherently different from other microbe-based immunotherapeutic strategies that typically just tickle immune cells from the outside," said Barbara Fox, senior research associate of Microbiology and Immunology.
"By gaining preferential access to the inside of powerful innate immune cell types, our mutated strain of T gondii reprogrammes the natural power of the immune system to clear tumour cells and cancer," Fox said.
Since it isn't safe to inject a cancer patient with live replicating strains of T gondii, Bzik and Fox created "cps," an immunotherapeutic vaccine.
Based on the parasite's biochemical pathways, researchers delete a Toxoplasma gene needed to make a building block of its genome and create a mutant parasite that can be grown in the laboratory but is unable to reproduce in animals or people.
Even when the host is immune deficient, cps still retains that unique biology that stimulates the ideal vaccine responses.
"Aggressive cancers too often seem like fast moving train wrecks. Cps is the microscopic, but super strong, hero that catches the wayward trains, halts their progression, and shrinks them until they disappear," said Bzik.
Published laboratory studies from the Geisel School of Medicine labs have tested the cps vaccine in extremely aggressive lethal mouse models of melanoma or ovarian cancer and found unprecedented high rates of cancer survival.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 16 2014 | 3:17 PM IST

Next Story